semaglutide

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
05020142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Despite common mechanisms of actions, glucagon-like peptide-1 receptor agonists differ in structure, pharmacokinetic… (More)
Is this relevant?
2018
2018
Context Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type… (More)
Is this relevant?
2017
2017
BACKGROUND Despite a broad range of pharmacological options for the treatment of type 2 diabetes, optimum glycaemic control… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
BACKGROUND Several pharmacological treatment options are available for type 2 diabetes; however, many patients do not achieve… (More)
Is this relevant?
2017
2017
BACKGROUND Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for once-weekly subcutaneous administration… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with… (More)
Is this relevant?
2016
2016
OBJECTIVE To investigate the dose-response relationship of semaglutide versus placebo and open-label liraglutide in terms of… (More)
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2015
2015
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2015
2015
The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Increased pancreas mass and glucagon-positive adenomas have been suggested to be a risk associated with sitagliptin or exenatide… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?